Market capitalization | $333.88m |
Enterprise Value | $195.94m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.89 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-52.66m |
Free Cash Flow (TTM) Free Cash Flow | $-59.24m |
Cash position | $141.24m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
4 Analysts have issued a AVROBIO Inc forecast:
4 Analysts have issued a AVROBIO Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.20 -1.20 |
33%
33%
|
|
EBITDA | -51 -51 |
26%
26%
|
EBIT (Operating Income) EBIT | -53 -53 |
27%
27%
|
Net Profit | -50 -50 |
508%
508%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alise Reicin |
Employees | 51 |
Founded | 2015 |
Website | www.tectonictx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.